B-cell- and plasma-cell-targeted therapies, including APRIL and BAFF inhibitors, represent a progression toward addressing the underlying immunological dysregulation characterizing IgA nephropathy [9,10,11,12,13,14]. Here, TNFSF13B is linked to IgA glomerulonephritis.